Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ascendis Pharma ( (ASND) ) has issued an update.
On April 8, 2026, Ascendis Pharma reported new Week 52 data from its Phase 2 COACH trial evaluating once-weekly combination therapy with TransCon CNP and TransCon hGH in children with achondroplasia. The results build on previously disclosed growth-velocity gains by showing that adding TransCon hGH appears to accelerate and broaden skeletal benefits without new safety issues so far, potentially strengthening Ascendis’ position in treatments for short stature with growth hormone sufficiency.
The company highlighted unprecedented improvements in arm span, with TransCon CNP–naïve children gaining an average 9.4 cm and previously treated children gaining 7.9 cm, changes that approach the magnitude of limb-lengthening surgery but without its high complication risk. Additional findings included greater increases in spinal interpedicular distance and enhanced straightening of lower limbs versus TransCon CNP monotherapy, and all enrolled children completed 52 weeks of therapy and remain on treatment, supporting continued clinical development and investor interest in the combination regimen.
The most recent analyst rating on (ASND) stock is a Buy with a $342.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
Spark’s Take on ASND Stock
According to Spark, TipRanks’ AI Analyst, ASND is a Neutral.
The score is driven primarily by improving fundamentals (rapid revenue growth, strong margins, and a move to positive operating/free cash flow) but is held back by balance-sheet risk (negative equity and high debt) and unprofitable earnings (negative P/E). Technicals are neutral-to-slightly cautious, while the latest earnings call adds support via upbeat guidance and commercial/pipeline momentum despite elevated operating expenses and near-term volatility risks.
To see Spark’s full report on ASND stock, click here.
More about Ascendis Pharma
Ascendis Pharma A/S is a Denmark-based biopharmaceutical company focused on developing long-acting therapies using its TransCon technology platform. The company’s pipeline targets endocrine and rare diseases, including treatments for growth disorders such as achondroplasia and growth hormone deficiency, aiming to offer differentiated, once-weekly injectable therapies in these specialty markets.
Average Trading Volume: 680,775
Technical Sentiment Signal: Buy
Current Market Cap: $13.53B
Learn more about ASND stock on TipRanks’ Stock Analysis page.